Insulin resistance and fertility in polycystic ovary syndrome.
Authors:
- A AlbuAAA Albu
- M ConstantinMCM Constantin
- Ga DobriGDGa Dobri
Open Access
- 1 October 2008
- journal article
- review article
- Vol. 1 (4) , 415-422
Abstract
Polycystic Ovary Syndrome (PCOS) represents a common endocrinopathy, with anovulation and hyperandrogenism as cardinal symptoms. In recent years it has been recognized that insulin resistance is an intrinsec feature of the disorder and plays a central role in pathogenesis. PCOS is associated with important reproductive morbidity as shown by high prevalence of anovulatory infertility, spontaneous abortion, gestational diabetes and pre–eclampsia. The association of insulin resistance with this reproductive pathology has been well documented. Due to major implication of insulin resistance in PCOS pathogenesis, insulin reduction strategies were studied as a possible treatment for infertility in PCOS patients. Weight loss, even modest was proved to be a simple and efficient method to improve reproductive parameters in PCOS patients and should be recommended to all overweight and obese patients with infertility. Metformin was showed to induce ovulation, at least in a subset of patients with PCOS, but there are not unequivocal proves concerning its efficacy for pregnancies and live–birth rate, mainly because few trials studied this aspect. Therefore there are not enough evidences to recommend metformin for infertility treatment in PCOS. Few small studies with newer thiazolidindiones suggest their efficacy for ovulation induction, but further extensive studies are needed to confirm these results. In conclusion, reduction of insulin resistance was proved to ameliorate ovulation rate in PCOS patients, but strong evidences to sustain the utility of insulin–sensitizing drugs as a therapeutic option for infertility are lacking. Future studies are needed to elucidate these aspects and to characterize the particular subtype of patients with higher probability to respond to this treatment.Keywords
This publication has 47 references indexed in Scilit:
- Use of Metformin in Polycystic Ovary SyndromeObstetrics & Gynecology, 2008
- The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndromeAmerican Journal of Obstetrics and Gynecology, 2007
- Metabolic characteristics of women with polycystic ovaries and oligo‐amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndromeClinical Endocrinology, 2007
- Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary SyndromeNew England Journal of Medicine, 2007
- A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate–resistant polycystic ovary syndromeFertility and Sterility, 2006
- Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of DosesThe Journal of Clinical Endocrinology & Metabolism, 2005
- The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndromeJournal of Endocrinological Investigation, 2005
- Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate aloneFertility and Sterility, 2001
- The prevalence of polycystic ovaries in women with a history of gestational diabetesClinical Endocrinology, 2000
- Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation1The Journal of Clinical Endocrinology & Metabolism, 2000